An Open-Label Study to Evaluate the Safety and | Clinical Research Studies Listing

Recruiting

99 years or below

All

Phase 2

9 participants needed

1 Location

Brief description of study

The main purpose of this research study is to test the safety and tolerability of PCS499 when given to individuals at a dose of 300 mg, twice a day for 1 week followed by giving PCS499 to individuals at a dose of 900 mg, twice a day, for remaining treatment period. Male or female patients age 18 to 80 years of age, Biopsy-confirmed diagnosis of NL. Procedures include labs, EKG's, Physical exams, questionnaires and a biopsy if not done with-in 5 years and photographs.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 12 Dec 2019. Study ID: 832022

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

An Open-Label Study to Evaluate the Safety and Tolerability of PCS499 for the treatment of Necrobiosis Lipoidica

Brief description of study

Eligibility of study

Find a site